Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SmithKline Beecham

This article was originally published in The Tan Sheet

Executive Summary

CEO Jan Leschly will retire following the annual general meeting for shareholders April 28, five months before he reaches mandatory retirement age. Leschly, 59, became chief exec of SB in 1994; he joined the company in 1990 as chairman of the worldwide pharmaceutical business. Under Leschly, SmithKline's consumer healthcare division moved to number two worldwide with the 1994 acquisition of Sterling Winthrop. It has grown recently with the company's launch of the NicoDerm CQ and Nicorette OTC smoking cessation products. Chief Operating Officer Jean-Pierre Garnier will succeed Leschly; the company does not expect to name a new COO

You may also be interested in...



Glaxo/SB Merger Talks Resume After Management, Manufacturing Changes

Manufacturing streamlining initiatives undertaken by Glaxo Wellcome and SmithKline Beecham in 1999 may have already begun the cost savings that can be expected from the combination of the British firms.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel